Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52

Journal of Nuclear Medicine

Volumn 55, Issue 1, 2014, Pages 9-14

  Mier, Walter ^a   Kratochwil, Clemens ^a   Hassel, Jessica C ^a   Giesel, Frederik L ^a   Beijer, Barbro ^a   Babich, John W ^b   Friebe, Matthias ^c   Eisenhut, Michael ^d   Enk, Alexander ^a   Haberkorn, Uwe ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Clinical Research   (United States)

^c BAYER PHARMA AG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Malignant melanoma; Melanin; Personalized medicine; Radionuclide therapy; Tumor targeting

Indexed keywords

(BENZO (1,3) DIOXOLO 5 CARBOXYLIC ACID (4 (2 DIETHYLAMINO ETHYLCARBAMOYL) 2 IODO 5 METHOXY PHENYL) AMIDE) I 123; (BENZO (1,3) DIOXOLO 5 CARBOXYLIC ACID (4 (2 DIETHYLAMINO ETHYLCARBAMOYL) 2 IODO 5 METHOXY PHENYL) AMIDE) I 131; ANTINEOPLASTIC AGENT; SODIUM PERCHLORATE; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; BENZAMIDE; BENZAMIDE DERIVATIVE; BENZO(1,3)DIOXOLO 5 CARBOXYLIC ACID (4 (2 DIETHYLAMINOETHYLCARBAMOYL) 2 IODO 5 METHOXYPHENYL)AMIDE; BENZO(1,3)DIOXOLO-5-CARBOXYLIC ACID (4-(2-DIETHYLAMINOETHYLCARBAMOYL)-2-IODO-5-METHOXYPHENYL)AMIDE; MELANIN; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; DRUG HALF LIFE; DRUG RETENTION; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; GENE EXPRESSION PROFILING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; ISOTOPE LABELING; MALE; MELANOMA; MELANOMA METASTASIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVERALL SURVIVAL; PATIENT SELECTION; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; RADIOIODINATION; RADIOISOTOPE THERAPY; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VERY ELDERLY; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; METASTASIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; PHENOTYPE; RADIOMETRY; RADIONUCLIDE THERAPY; RADIOTHERAPY; TUMOR TARGETING;

MALIGNANT MELANOMA; MELANIN; PERSONALIZED MEDICINE; RADIONUCLIDE THERAPY; TUMOR TARGETING;

ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; BENZODIOXOLES; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MELANINS; MELANOMA; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM METASTASIS; PHENOTYPE; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84894736485     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.112789     Document Type: Article

References (22)

1. Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst. 2001;93: 678-683.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56: 106-130.
3. Markovic SN, Erickson LA, Rao RD, et al.Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc. 2007;82: 490-513.
4. Sun W, Schuchter LM. Metastatic melanoma. Curr Treat Options Oncol. 2001;2: 193-202.
5. Croghan GA, Suman VJ, Maples WJ, et al. A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study. Cancer. 2010;116: 3463-3468.
6. Schild SE. Role of radiation therapy in the treatment of melanoma. Expert Rev Anticancer Ther. 2009;9: 583-586.
7. 99mTc complexes containing the N-(2-diethylaminoethyl)benzamide structural element. J Med Chem. 2002;45: 5802-5805.
8. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46: 1023-1027.
9. Recchia F, Candeloro G, Necozione S, Fumagalli L, Bratta M, Rea S. Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma. Anticancer Drugs. 2008;19: 201-207.
10. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364: 2507-2516.
11. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364: 2517-2526.
12. Michelot JM, Moreau MF, Veyre AJ, et al. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2- diethylaminoethyl 4-iodobenzamide). J Nucl Med. 1993;34: 1260-1266.
13. Larisch R, Schulte KW, Vosberg H, Ruzicka T, Muller-Gartner HW. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo. J Nucl Med. 1998;39: 996-1001.
14. 18F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration. J Nucl Med. 2011;52: 115-122.
15. Michelot JM, Moreau MF, Labarre PG, et al. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. J Nucl Med. 1991;32: 1573-1580.
16. Oltmanns D, Eisenhut M, Mier W, Haberkorn U. Benzamides as melanotropic carriers for radioisotopes, metals, cytotoxic agents and as enzyme inhibitors. Curr Med Chem. 2009;16: 2086-2094.
17. Wolf M, Bauder-Wust U, Mohammed A, et al. Alkylating benzamides with melanoma cytotoxicity. Melanoma Res. 2004;14: 353-360.
18. Dadachova E, Nosanchuk JD, Shi L, et al. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. Proc Natl Acad Sci USA. 2004;101: 14865-14870.
19. Revskaya E, Jongco AM, Sellers RS, et al. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine. Clin Cancer Res. 2009;15: 2373-2379.
20. Velazquez EF, Jungbluth AA, Yancovitz M, et al. Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM): correlation with prognostic factors. Cancer Immun. 2007;7: 11-17.
21. Willmore-Payne C, Holden JA, Tripp S, Layfield LJ. Human malignant melanoma: detection of BRAF-And c-kit-Activating mutations by high-resolution amplicon melting analysis. Hum Pathol. 2005;36: 486-493.
22. Schiffner S, Chen S, Becker JC, Bosserhoff AK. Highly pigmented Tg(Grm1) mouse melanoma develops non-pigmented melanoma cells in distant metastases. Exp Dermatol. 2012;21: 786-788.